BRENUS-PHARMA
22.1.2024 18:01:34 CET | Business Wire | Press release
Brenus Pharma announces the financing of nearly 5 million euros for its STC-1010 project as the winner of the "Innovations in Biotherapy and Bioproduction" call for proposals from France 2030. Operated on behalf of the French government by Bpifrance, this support aims to catalyze and maintain excellence in biotherapy research and places Brenus Pharma among the key players of French Biotherapy.
STC-1010: A proteomics-guided cellular immunotherapy to fight cancer relapses.
Brenus Pharma has developed the anti-cancer vaccine STC-1010, targeting metastatic colorectal cancer (mCRC), second leading cause of cancer mortality worldwide. The project's aims are to finalize the development of STC-1010, ensuring its bioproduction and industrialization, and to carry out, in support of the fundraising, the first phase Ia/Ib clinical trial. These crucial steps, which follow the regulatory validation of the pre-clinical package, will provide the first data on the safety and efficacy of the vaccine in humans.
"Brenus Pharma stands out for its innovative platform that generates new cellular and vaccine immunotherapies guided by proteomics. These therapies are based on in vitro reproduction of the proteomic signatures of resistant tumors. This innovation allows us to educate the patients' immune system to recognize and target these resistance mechanisms that usually escape its surveillance. We thank the State via France 2030 for this support, which validates Brenus' technological approach and should accelerate its availability to patients," said Paul BRAVETTI, CEO of Brenus Pharma.
Brenus Pharma, strong territorial anchorage to consolidate the French Advanced Therapy Medicinal Product (ATMP) industry.
This project is part of a national effort to consolidate the French innovative therapy (ATMP) drug industry through the Biotherapy-Bioproduction acceleration strategy coordinated by the French Health Innovation Agency, involving many SMEs with strong regional ties. Brenus aims to contribute not only to scientific and therapeutic innovation in the field of oncology, but also to the influence of French biotechnological excellence.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240122731907/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hightouch Launches Match Booster in Europe, Raising Match Rates Without Compromising Compliance3.11.2026 09:02:00 CET | Press release
In a five-market pilot, Match Booster beat a global media company’s existing onboarding provider in every head-to-head test, matching 15%+ more people on average and up to 90% more in a single test. Hightouch, the leading agentic marketing platform, today launched Match Booster in the UK, Germany, France, Spain, and Italy. Match Booster helps brands, agencies, media networks, and publishers reach more of their customers on more than 50 ad platforms, including Google, Meta, Amazon, TikTok, and The Trade Desk, by adding to their consented first-party data instead of replacing it. Until now, European advertisers have had two options. They could send first-party data to ad platforms alone and accept the match rates they got. Or they could hand it to a traditional onboarding provider that swaps it for a proprietary ID and drops any customer its graph can’t find, sometimes leaving audiences smaller than they started. Global companies also end up running separate US and EU workflows to meet d
Building on Netherlands NextGen Momentum, Trilliant Showcases Why the Next Generation of AMI is Being Defined by Choice at Enlit Europe 20263.11.2026 09:00:00 CET | Press release
Trilliant highlights how open, interoperable technologies help utilities modernize, protect investments, and preserve long-term flexibility Trilliant, a technology platform partner enabling utilities to gain real-time visibility and optimize performance across an increasingly dynamic energy landscape, will showcase its Power of Choice approach at Enlit Europe 2026, taking place 10–12 November in Vienna, Austria. The company will highlight how intelligent software and device-independent technologies help utilities modernize infrastructure and prepare for evolving grid demands. Trilliant’s participation at Enlit Europe follows its recent selection by Dutch distribution system operators to support the Netherlands’ NextGen smart metering programme. Trilliant’s role includes developing and delivering gateways supported by its transformed UnitySuite® platform, which will be demonstrated during the conference. At Enlit Europe, Trilliant will spotlight its Power of Choice approach, enabling ut
Cambridge International AS & A Level June Series Results to Be Released Earlier From 20273.11.2026 08:05:00 CET | Press release
June series Cambridge International AS & A Level results moved two weeks earlierGives international students more time to confirm university places, apply for visas and arrange travel Students taking Cambridge International AS & A Levels will receive their June series exam results almost two weeks earlier from 2027. Results for the June 2027 series will be released on 28 July 2027, the International Education group at Cambridge University Press & Assessment (Cambridge) announced today. The change responds to feedback from schools, students and families that earlier results would make a practical difference. Earlier results give students more time to confirm university places, complete enrolment, apply for visas and arrange travel. Bringing the date forward will allow students to take up a university place in the same calendar year in some countries, where previously they could not. Earlier results will also give universities more time to review applications, confirm offers and resolve
Ant International and Bank Partners Achieve Real-Time Cross-Bank Liquidity Management through Tokenised Deposits via CeBM under HKMA’s EnsembleTX3.11.2026 05:10:00 CET | Press release
Transfers were among the first batch of live transactions completed under EnsembleTX, unlocking 24/7 liquidity access and near-instant settlement Following the Hong Kong Monetary Authority’s (HKMA) announcement on interbank settlement of tokenised deposit transactions under EnsembleTX, Ant International announced that it has achieved real-time cross-bank liquidity management with its key banking partners as part of its active participation in EnsembleTX. In close collaboration with Bank of China (Hong Kong) (“BOCHK”, SEHK: 2388), China Construction Bank (Asia) (“CCB (Asia)”) and HSBC (SEHK: 5), Ant International successfully completed a series of live HKD interbank transactions between September and October 2026: BOCHK interbank transactions with CCB (Asia) CCB (Asia) interbank transactions HSBC interbank transactions Executed using tokenised deposit settled through the HKMA’s Central Bank Money (CeBM), the transfers were initiated via Ant International’s proprietary blockchain-based w
SuperElastic* Material Unveiled by Angelalign2.11.2026 18:46:00 CET | Press release
New, Improved Clear Aligner Material Gives Orthodontists More Control Angelalign Technology Inc. (6699.HK) (“Angel”)http://www.angelaligner.com, a global clear aligner leader, today unveiled SuperElastic (MC-SE*), a new propietary aligner material that is a significant breakthrough in performance over its current material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261102654659/en/ Specialists in orthodontics have long asked for new aligner materials that enable better treatment for complex cases: biologically safe force levels, a large elastic working range, and strength and toughness. MC-SE* provides all of them. “Angel is commited to innovation and never settling for 'good enough'. MC-SE* is the result of seven years of materials research, testing and manufacturing optimization. The new material aims to create a new generation of aligner material that allows orthodonists to differentiate their treatment from other tre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom